Trials / Completed
CompletedNCT02385721
Post-Authorization Long-term Safety Surveillance on Antihypertensive Treatment With Kanarb® (Fimasartan)
A Prospective, Observational, Post-Authorization Long-term Safety Surveillance on Antihypertensive Treatment With Kanarb® (Fimasartan) During 1 Year Among 20 and Older Diagnosed With Essential Hypertension
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 601 (actual)
- Sponsor
- Boryung Pharmaceutical Co., Ltd · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
Evaluated the incidence and characteristics of adverse events during the treatment for Kanarb tablet.
Detailed description
This study is designed to evaluate the incidence and characteristics (profile, relationship to the study drug, severity, and outcome) of adverse events (AEs) observed during 1-year treatment with Kanarb tablet® (fimasartan)
Conditions
Timeline
- Start date
- 2013-05-01
- Primary completion
- 2017-07-01
- Completion
- 2018-04-01
- First posted
- 2015-03-11
- Last updated
- 2019-03-06
- Results posted
- 2019-02-01
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT02385721. Inclusion in this directory is not an endorsement.